Carolyn Luscombe Email

Director Translational Sciences . Cocrystal Pharma

Current Roles

Employees:
22
Revenue:
$3.4M
About
Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 54% of the Company. Corporate investors include OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd.
Cocrystal Pharma Address
19805 North Creek Parkway
Tucker, GA
United States
Cocrystal Pharma Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.